Research and Markets (http://www.researchandmarkets.com/research/wcw3vv/resistant) has announced the addition of the "Resistant Pseudomonas Aeruginosa Infections - Pipeline Review, H2 2015" report to their offering.

This report provides comprehensive information on the therapeutic development for Resistant Pseudomonas Aeruginosa Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Resistant Pseudomonas Aeruginosa Infections and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Key Topics Covered:

  1. Introduction
  2. Resistant Pseudomonas Aeruginosa Infections Overview
  3. Therapeutics Development
  4. Pipeline Products for Resistant Pseudomonas Aeruginosa Infections - Overview
  5. Pipeline Products for Resistant Pseudomonas Aeruginosa Infections - Comparative Analysis
  6. Resistant Pseudomonas Aeruginosa Infections - Therapeutics under Development by Companies
  7. Resistant Pseudomonas Aeruginosa Infections - Therapeutics under Investigation by Universities/Institutes
  8. Resistant Pseudomonas Aeruginosa Infections - Pipeline Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Resistant Pseudomonas Aeruginosa Infections - Products under Development by Companies
  13. Resistant Pseudomonas Aeruginosa Infections - Products under Investigation by Universities/Institutes
  14. Resistant Pseudomonas Aeruginosa Infections - Companies Involved in Therapeutics Development
  • Achaogen Inc.
  • AstraZeneca Plc
  • Biolytics Pharma
  • CSA Biotechnologies LLC
  • LegoChem Biosciences, Inc
  • Melinta Therapeutics, Inc
  • Phico Therapeutics Limited
  • Phylogica Limited
  • Shionogi & Co., Ltd.
  • Zambon Company S.p.A.

For more information visit http://www.researchandmarkets.com/research/wcw3vv/resistant